• Hansoh Pharma presented Phase 1 results for cancer drug HS-20122 at ESMO in Madrid on October 24, 2026.
• The treatment showed antitumor activity across advanced solid tumors, particularly EGFR-mutated lung cancer following failure of EGFR-targeted therapy.
• Safety was manageable, with most treatment-related adverse events mild to moderate; serious events primarily involved blood abnormalities.
• The findings support further development in multiple solid tumors, including EGFR-mutated lung cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 25, 2026, and is solely responsible for the information contained therein.